Gilead Sues Sigmapharm Over Hepatitis B Generic

Law360, New York (October 4, 2010, 4:13 PM EDT) -- Gilead Sciences Inc. has sued Sigmapharm Laboratories LLC over its attempt to introduce a generic version of chronic hepatitis B drug Hepsera despite two patents covering the treatment.

In a complaint filed Friday in the U.S. District Court for the Eastern District of Pennsylvania, Gilead claims Bensalem, Pa.-based Sigmapharm has sought approval from the U.S. Food and Drug Administration to manufacture a generic form of Hepsera before the expiration of the patents-in-suit.

By dint of its abbreviated new drug application Sigmapharm has alleged that the two...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.